Stroke är den näst vanligaste dödsorsaken i världen och den tredje vanligaste orsaken till funktionshinder. I Sverige drabbas cirka 25 000 personer årligen. Patienter med stroke är den enskilda sjukdomsgrupp som står för flest vårddagar på svenska sjukhus. I akut behandling av stroke används termen ”Time is Brain”, då det dör cirka två miljoner hjärnceller vid varje minuts fördröjning. Det har utförts stora ansträngningar i två decennier för att effektivisera akuta vårdkedjan vid stroke. Endast två till 13 procent av patienterna får möjlighet till behandling på sjukhus med trombolys och antalet trombektomi är mycket lägre. Av de patienter som får trombolys är det cirka en till tio procent som får trombolys inom en timme efter symtomdebut. Främsta orsaken till underbehandling är att patienter inte når sjukhuset tillräckligt snabbt för att undersökas och behandlas inom det smala terapeutiska fönstret. I Sverige år 2016 anlände 33 procent av patienterna med stroke inom tre timmar till sjukhus och antalet har inte ökat sedan 2011. Det var angeläget att beskriva befintlig kunskap om hur ambulanspersonal kan påskynda behandlingen för patienter med stroke. Syftet var att belysa ambulansteamets betydelse för att minska tiden från symtomdebut till behandling av stroke Metoden för studien var en litteraturöversikt med 16 vetenskapliga artiklar publicerade mellan åren 2012 och 2017. Artiklarna söktes i databaserna PubMed och Cinahl. Resultatet som framkom av de valda artiklarna kunde sammanställas genom två huvudkategorier och fem underkategorier. Den ena huvudkategorin handlade om ambulanspersonalens omhändertagande av patienter med stroke. Den andra huvudkategorin handlade om ambulanspersonalens kunskap. Resultatet visade att ambulanspersonal kunde genom teamarbete i ett ambulansfordon med en inbyggd röntgenapparat, kallad Mobile Stroke Unit (MSU), förkorta tiden från symtomdebut till behandling. MSU var mellan 25 till 81 minuter snabbare, jämfört med konventionell ambulans. Dörr-till-nål tiderna (tiden från det att patient ankommer till sjukhus till start av trombolys) förbättrades med fem minuter när ambulanspersonal förvarnade sjukhusen med strokelarm. Ambulanspersonal förbättrade inte akuta vårdkedjan med hjälp av telemedicin. Patienter med stroke i bakre cirkulationen hade en timmes prehospitala fördröjningar jämfört med patienter med stroke i främre cirkulationen. Akuta vårdkedjan förbättrades inte när ambulanspersonal fick en timmes föreläsning om stroke. Slutsatsen var att ambulansteamet förkortade tiden från symtomdebut till behandling genom teamarbete i Mobile Stroke Unit. Ambulansteamet förbättrade inte akuta vårdkedjan med hjälp av telemedicin. Det skedde prehospitala fördröjningar för patienter med stroke i bakre cirkulationen. Ytterligare forskning av MSU behövs. Framtida randomiserade studier bör undersöka kliniskt utfall och kostnadseffektivitet. Det bör även forskas i området om hur ambulansteamet kan minska tiden från symtomdebut till behandling av stroke i en konventionell ambulans. Nyckelord: stroke, ambulanspersonal, tid, prehospital trombolys, Mobile Stroke Unit. / Stroke is the second most common cause of death in the world and the third most common reason cause for disability. In Sweden approximately 25000 people are affected annually. Patients whit stroke are the group that accounts for most care days in Swedish hospitals. In acute stroke treatment, the term "Time is Brain" is used, as about two million brain cells die at every minute delay. Despite two decades of substantial efforts to streamline systems of care in stroke, only two to 13 percent of patients receive the treatment thtombolysis in a hospital and the rates of delivery of thrombectomy are far lower. Of the patients who are treated with thrombolysis, approximately one to ten percent receives thrombolysis within one hour after symptom on set. The main reason for such undertreatment is that patients do not reach the hospital quickly enough to be assesed and treated within the narrow therapeutic window. In Sweden 2016, only 33 percent of patients with stroke arrived to the hospital within three-hours after symptom on set and the rates has not increased since 2011. It was important to describe existing knowledge about how the ambulance staff can shorten the time from symptom on set to treatment for stroke patients. The aim was to highlight the importance of the ambulance staff to reduce the time from symptom on set to stroke treatment. The method of the study was a literature review of 16 scientific articles published between the years 2012 and 2017. The articles were searched in the PubMed and Cinahl databases. The results obtained from the selected articles were compiled by two main categories and five subcategories. One main category was about the care of ambulance staff in patients with stroke. The second main category was about the ambulance staff's knowledge. The result showed that ambulance staff can shorten the time from symptom on set to treatment though teamwork in an ambulance with an inbuilt CT-scan, called Mobile Stroke Unit (MSU). MSU was between 25 minutes and 81 minutes faster, compared to conventional ambulance. Door-to-Needle time (time from patient arriving to hospital until start of thrombolysis) improved with five minutes when ambulance staff warned the hospital with a strokealarm. Ambulance staff did not improve the system of care using telemedicine. Patients with stroke in the posterior circulation had one hour of prehospital delays compared with patients with stroke in the anterior circulation. The system of care did not improve when ambulance staff received an hour's lecture on stroke. The conclusion was that ambulance staff shortened the time from symptom on set to treatment through teamwork in the Mobile Stroke Unit. Ambulance staff did not improve the system of care using telemedicine. There where prehospital delays for patients with stroke in the posterior circulation. Further research of MSU is required. Further randomized studies should investigate clinical outcome and cost-effectiveness. It should also be researched in the area of how the ambulance staff can shorten the time from symptom on set to treatment in a conventional ambulance Keywords: stroke, emergency medical service, time, prehospital thrombolysis, Mobile Stroke Unit.

Anfang der 90er Jahre entwickelten sich neue pharmakologische Behandlungsstrategien des akuten Myokardinfarktes durch GP IIb/IIIa- Rezeptorantagonisten. Der optimale Zeitpunkt der Administration und die Wahl des Therapieregimes ist Diskussionsstoff. Ziel dieses Konzeptes ist es, mit der Verlagerung des Therapiebeginns in die Prähospitalphase die Zeit bis zur Reperfusion des Infarktareals zu minimieren. Die Schaffung einer Hotline zum Kardiologen bietet dem Notarzt fachlichen Rat. Bestehen keine logistischen Hindernisse innerhalb von 60 Minuten wird eine Herzkatheteruntersuchung, bei Überschreiten wird die Kombinationslysetherapie mit interventioneller Versorgung des Infarktgefäßes binnen 24 Stunden durchgeführt. Ziel der Datenanalyse war nachzuweisen, ob die Sterblichkeit von bis zu 15% im Vergleich zu Registerstudien gleicher Konzeption niedriger und die Krankenhausverweildauer von 12 Tagen kürzer ist. Im Erfassungszeitraum wurden 347 Patienten, davon 254 Männer (73%) und 93 Frauen (27%) behandelt. Das Alter im Median betrug 62 Jahre. 57 (16%) Patienten wurden prähospital lysiert, 81 (20%) inhospital. 218 (63%) wurden mittels primärer interventioneller Therapie behandelt. Die Aufenthaltsdauer im Krankenhaus aller Patienten betrug 6 Tage. Der Aufenthalt im Median auf der Intensivstation betrug in der Gruppe der lysierten Patienten 1,0 Tage (prähospital 0,8 vs inhospital 1,3 Tage), in der primären Herzkathetergruppe 0,9 Tage. 8 MACE traten auf. Die Kankenhausmortalität betrug 6,3 %, in der Gruppe der mittels Lyse behandelten Patienten 9,3% (prähospital 12,3%, inhospital 6,9%) und in der primär interventionell versorgten Gruppe 4,6%. Die Mortalität der initial hämodynamisch stabilen Patienten lag unter 3%. Die 180 Tage Mortalität betrug gesamt 10,8%, in der Lyse Gruppe 11,7% (prähospital 14,0% vs. inhospital 9,9%) und 9,2% in der interventionell behandelten Gruppe. Zu keinem Zeitpunkt bestanden signifikante Unterschiede. Die aggressive Therapie des akuten Myokardinfarkts beinhaltet diesen Daten zufolge kein Risiko für die Patienten und zeigt im Vergleich zu Registerstudien ähnlicher Konzeption eine niedrigere Krankenhaussterblichkeit und eine kürzere Krankenhausverweildauer. Diese Arbeit ist der Erinnerung an meinem geschätzten Freund und Kollegen Oberarzt Dr. med. Torsten Thieme gewidmet, der viel zu früh verstorben ist. / In the early 90’s a new class of agents blocking the GPIIb/IIIa-receptors on the platelet surface was developed capable of speeding up pharmacological reopening of infarct related arteries. The optimal time of administration remains subject of discussion. Despite these advantages hospital mortality in great registries is still more than 15% and hospital stay 12 days. By January 1st, 1999 a hotline between ambulance car and the interventional cardiologist was instituted. In each case management with either immediate PCI under GPIIb/IIIa-inhibition or half dose thrombolytics and full dose GPIIb/IIIa-inhibitors, if possible, started out of hospital. The approach was to see if the mortality was lower and the hospital stay shorter than in comparable registries. During September 1999 – December 2001 347 patients aged 26 to 92 years (60 plus minus 13) were treated. Median age was 62 years. There were 93 female (27%) and 254 male patients (73%). 57 (16%) patients received out of hospital thrombolysis, 81 (20%) were treated inhospital and 218 (63%) patients underwent primary cardiac catheterization. Overall inhospital median stay was 6.0 days. The median ICU-time for all thrombolysed patient was 1,0 days (prehospital 0,8 vs inhospital 1,3 days) and in the interventionally treated group 0,9 days. In all patients .8 MACE events occurred. Overall hospital mortality was 6,3 %, in the group of thrombolysed patients 9,3% (prehospital 12,3%, inhospital 6,9%). Shock excluded mortality was below 3%. 346/347 patients reached 180 days of follow-up. 180 days mortality overall was 10,8%, for the thrombolysed group 11,7% (prehospital 14,0% vs. inhospital 9,9%) and 9,2% in the interventionally treated group. There was no statistical significant difference. The time optimized individualized treatment assignment to pharmacological therapy followed by routine facilitated PCI within 24 hours is an approach that is more aggressive than currently recommended in the guidelines, but seems to offer further improvements of outcome with no further riscs for patients with AMI in comparison to other registries. This work is published in memory of my beloved friend and colleague Torsten Thieme, MD, who died much to young.

<p>We evaluated, in patients with ST-elevation myocardial infarction (STEMI) treated with thrombolytics, admission Troponin T (tnT), ST-segment resolution and admission N-terminal pro-brain natriuretic peptide (NT-proBNP) for early risk stratification as well as time delays and outcome in real life patients according to prehospital or in-hospital thrombolytic treatment. Also, baseline characteristics, treatments and outcome in patients enrolled in the ASSENT-2 trial in Sweden and in patients not enrolled were evaluated. </p><p>TnT (n=881) and NT-proBNP (n=782) on admission and ST-resolution at 60 minutes (n=516) in patients from the ASSENT-2 and ASSENT-PLUS trials were analysed. Elevated levels of NT-proBNP and tnT on admission were both independently related to one-year mortality. However, when adding information on ST-resolution (</≥50%) 60 minutes after initiation of thrombolytic treatment, tnT no longer contributed independently to mortality prediction. High and low risk patients were best identified by a combination of NT-proBNP and ST-resolution at 60 minutes.</p><p>We investigated consecutive STEMI patients included in the RIKS-HIA registry between 2001 and 2004, if they were ambulance transported and had received prehospital (n=1690) or in-hospital (n=3685) thrombolytic treatment. Prehospital diagnosis and thrombolysis reduced the time to thrombolysis by almost one hour, were associated with better left ventricular function and fewer complications and reduced the adjusted one-year mortality by 30% compared with in-hospital thrombolysis. </p><p>Prospective data from the RIKS-HIA registry on STEMI patients treated with thrombolytics were linked to data on trial participants in the ASSENT-2 trial of thrombolytic agents and used for direct comparisons. Patients treated with thrombolytics and not enrolled in a clinical trial at trial hospitals (n=2048) had higher risk characteristics, more early complications and twice as high adjusted one-year mortality compared to those enrolled (n=729). One major reason for the difference in outcome appeared to be the selection of less critically ill patients to the trial.</p>

We evaluated, in patients with ST-elevation myocardial infarction (STEMI) treated with thrombolytics, admission Troponin T (tnT), ST-segment resolution and admission N-terminal pro-brain natriuretic peptide (NT-proBNP) for early risk stratification as well as time delays and outcome in real life patients according to prehospital or in-hospital thrombolytic treatment. Also, baseline characteristics, treatments and outcome in patients enrolled in the ASSENT-2 trial in Sweden and in patients not enrolled were evaluated. TnT (n=881) and NT-proBNP (n=782) on admission and ST-resolution at 60 minutes (n=516) in patients from the ASSENT-2 and ASSENT-PLUS trials were analysed. Elevated levels of NT-proBNP and tnT on admission were both independently related to one-year mortality. However, when adding information on ST-resolution (&lt;/≥50%) 60 minutes after initiation of thrombolytic treatment, tnT no longer contributed independently to mortality prediction. High and low risk patients were best identified by a combination of NT-proBNP and ST-resolution at 60 minutes. We investigated consecutive STEMI patients included in the RIKS-HIA registry between 2001 and 2004, if they were ambulance transported and had received prehospital (n=1690) or in-hospital (n=3685) thrombolytic treatment. Prehospital diagnosis and thrombolysis reduced the time to thrombolysis by almost one hour, were associated with better left ventricular function and fewer complications and reduced the adjusted one-year mortality by 30% compared with in-hospital thrombolysis. Prospective data from the RIKS-HIA registry on STEMI patients treated with thrombolytics were linked to data on trial participants in the ASSENT-2 trial of thrombolytic agents and used for direct comparisons. Patients treated with thrombolytics and not enrolled in a clinical trial at trial hospitals (n=2048) had higher risk characteristics, more early complications and twice as high adjusted one-year mortality compared to those enrolled (n=729). One major reason for the difference in outcome appeared to be the selection of less critically ill patients to the trial.